Case Details
- Citation: [2013] SGHCR 7
- Case Title: AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd
- Court: High Court of the Republic of Singapore
- Date of Decision: 15 March 2013
- Coram: Justin Yeo AR
- Case Number: Suit No 416 of 2011
- Related Summons: Summons No 471 of 2013
- Plaintiff/Applicant: AstraZeneca AB (SE)
- Defendant/Respondent: Sanofi-Aventis Singapore Pte Ltd
- Counsel for Plaintiff: Mr Alvin Lim and Mr Sandeep Menon (Rodyk & Davidson LLP)
- Counsel for Defendant: Mr Jason Chan, Mr Melvin Pang and Ms Anna Toh (Amica Law LLC)
- Legal Areas: Patents and Inventions – Infringement; Civil Procedure – Pleadings; Further & Better Particulars
- Statutes Referenced: Medicines Act; Patents Act; Rules of Court (Cap 322, R 5, 2006 Rev Ed)
- Procedural Posture: Application for further and better particulars under O 18 r 12 and O 87A r 2
- Prior Related Decision: AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd [2012] SGHC 16
- Judgment Length: 14 pages (8,430 words)
Summary
This High Court decision concerns a procedural dispute in patent-related litigation arising from Singapore’s “patent linkage” regime under the Medicines Act. AstraZeneca, the proprietor of Singapore Patent No SG 89993, sued Sanofi seeking declarations that Sanofi’s rosuvastatin products would infringe AstraZeneca’s patent. Sanofi then applied for an order compelling AstraZeneca to provide further and better particulars of infringement. The application was brought under O 18 r 12 and O 87A r 2 of the Rules of Court.
The court accepted that the ordinary principles governing pleadings and particulars apply to actions under the Medicines Act, but emphasised that patent infringement actions also attract a specific statutory pleading requirement under O 87A r 2(2). The key question was the extent and nature of the “particulars of infringement” that a patentee must provide, including whether the patentee must give a definitive construction of the patent claims at the pleading stage or whether it suffices to identify the claims relied upon and at least one instance of each type of infringement alleged.
In analysing the “office” of particulars of infringement, the court traced how English law has evolved from a traditional reluctance to require claim construction at the particulars stage to a more modern approach that focuses on ensuring the defendant is not taken by surprise and can prepare its evidence and defences. The court ultimately determined that the particulars sought by Sanofi went beyond what was required at that stage, and that AstraZeneca’s pleaded case was sufficiently particularised to meet the purpose of O 87A r 2(2) and O 18 r 12.
What Were the Facts of This Case?
AstraZeneca AB (SE) was the proprietor of Singapore Patent No SG 89993, entitled “Pharmaceutical Compositions Comprising a HMG COA Reductase Inhibitor”. The invention’s feature, as described in the patent specifications, concerned pharmaceutical compositions comprising rosuvastatin (the “Agent”) as an active ingredient and an inorganic salt with a multivalent cation, subject to exclusions (the inorganic salt is neither hydrotalcite nor synthetic hydrotalcite, and the counter anion is not a phosphate). The specification also indicated that the composition is preferably in tablet form.
The patent contained 27 claims. Claim 1, in broad terms, covered a pharmaceutical composition for treating high cholesterol comprising (i) rosuvastatin as the active ingredient and (ii) an inorganic salt with a multivalent cation, with the specified exclusions. AstraZeneca’s infringement case, as pleaded, was that Sanofi’s products would infringe all 27 claims if Sanofi carried out specified acts in Singapore, including disposal, offer to dispose, use, import, and keeping.
On 1 April 2011, Sanofi applied to the Health Sciences Authority (HSA) for product licences for its Rosucard Film-coated Tablets in 10mg, 20mg and 40mg dosage forms. Under the Medicines Act patent linkage provisions, AstraZeneca was served with a Notice to Proprietor of Patent on 26 April 2011 pursuant to s 12A(3)(a). The notice informed AstraZeneca that Sanofi had submitted the HSA applications, thereby triggering the statutory mechanism that can impose a 30-month moratorium on processing the product licence applications.
On 10 June 2011, AstraZeneca commenced the action seeking a declaration of infringement. The practical effect of commencing the action was to set in place the 30-month moratorium on the processing of Sanofi’s product licence applications, as provided by s 12A(6) of the Medicines Act read with regulation 5B(4) of the Medicines (Licensing, Standard Provisions and Fees) Regulations. AstraZeneca later filed an amended Statement of Claim (Amendment No 1) dated 5 July 2011.
What Were the Key Legal Issues?
The immediate issue before the court was whether AstraZeneca’s amended Statement of Claim (Amendment No 1) provided sufficiently detailed “further and better particulars” of infringement, as required by O 18 r 12 and O 87A r 2 of the Rules of Court. Sanofi’s application effectively challenged whether AstraZeneca had pleaded the infringement case with the clarity and precision necessary to inform Sanofi of the nature of the case it had to meet and to prevent surprise at trial.
A second, more substantive issue was the scope of the pleading requirement under O 87A r 2(2). That rule requires that, in patent infringement actions, the plaintiff must serve with the statement of claim particulars of the infringement relied on, showing which patent claims are alleged to be infringed and giving at least one instance of each type of infringement alleged. The court had to decide what “particulars of the infringement” means in practice, and whether it includes requiring the patentee to adopt and plead a definitive construction of the patent claims at the particulars stage.
Finally, the court had to consider the interaction between the Medicines Act cause of action and the Patents Act infringement framework. Although the earlier striking-out application had already established that s 12A of the Medicines Act creates an independent cause of action that requires only a prospect of infringement, the present dispute was still about pleadings: what level of detail is required when the litigation is triggered by the patent linkage regime rather than a conventional infringement action.
How Did the Court Analyse the Issues?
The court began by addressing the procedural framework. Both parties proceeded on the basis that the Rules of Court relating to pleadings and particularity apply similarly to actions under the Medicines Act. The court agreed, noting that O 18 r 12 provides the court with a discretionary power to order a party to serve particulars of any claim, defence or other matter stated in a pleading. The court reiterated the “trite” purposes of particulars: to inform the other side of the nature of the case to be met, to prevent surprise at trial, and to enable the other side to know what evidence it ought to prepare. Particulars also promote clarity and precision of issues and reduce the need for later remedial steps.
Turning to patent-specific pleading requirements, the court emphasised that O 87A r 2(2) imposes an additional requirement beyond the general O 18 r 12 regime. Under O 87A r 2(2), the plaintiff must provide particulars of infringement relied on, identifying which claims are alleged to be infringed and giving at least one instance of each type of infringement alleged. The court observed that O 87A r 2(2) does not itself define the extent of the particulars required, which necessitated recourse to case law describing the “office” of particulars of infringement.
To determine the proper scope of particulars, the court examined the evolution of English law. It referred to Wenham Co Ltd v Champion Gas Lamp Co Ltd and Todlenhaupt and Co [1891] 8 RPC 22, which articulated a traditional position: a patentee is not ordinarily ordered to give particulars of the construction it proposes to put on the patent claims at the particulars stage. In Wenham, the court held that the purpose of particulars was to tell the defendant what the plaintiff says it has done in infringement, and that requiring a definite construction at that stage was not appropriate.
The court then contrasted Wenham with later developments, including Marsden v Albrecht and Albrecht (1910) 27 RPC 785, where the Court of Appeal required more specificity because the particulars effectively alleged infringement of all claims without meaningful differentiation. The court’s analysis indicated that the sufficiency of particulars is fact-sensitive and depends on whether the defendant is genuinely able to understand the case it must meet and prepare its evidence and defences, including validity challenges.
Although the judgment extract provided in the prompt is truncated, the court’s approach is clear from the portion reproduced: it treated the “office” of particulars as a practical mechanism to ensure fairness in litigation. The court recognised that the legal principles governing particulars have changed over time, and it set out the need to examine those changes to determine what is required in the modern procedural context. The court also noted that the determination of sufficiency involves questions of fact, but the underlying legal principles remain anchored in the purposes of particulars and the specific requirements of O 87A r 2(2).
Applying these principles, the court considered the procedural history. AstraZeneca had already obtained discovery of the Product Descriptions of Sanofi’s products, including chemical composition and quantities of active pharmaceutical ingredients and excipients. This discovery reduced the risk that Sanofi would be taken by surprise about the factual basis for infringement allegations. Against that backdrop, the court assessed whether Sanofi’s request for further and better particulars was, in substance, an attempt to force AstraZeneca to plead claim construction arguments or to narrow the infringement case prematurely, rather than to clarify the pleaded infringement instances and the claims relied upon.
In the court’s view, the particulars required at this stage were those that meet the statutory minimum and the fairness objectives of pleadings: identifying the claims alleged to be infringed and providing at least one instance of each type of infringement alleged, without requiring a definitive construction of the patent claims. Where the requested particulars relate to construction disputes, the court treated them as matters for claim interpretation and evidence at the appropriate stage, not as a substitute for the minimum pleading requirement.
What Was the Outcome?
The court dismissed Sanofi’s application for further and better particulars. The practical effect was that AstraZeneca was not required to provide the additional level of detail sought by Sanofi in its letter of request and application, because the existing pleadings were sufficiently particularised for the purposes of O 18 r 12 and O 87A r 2(2).
For litigation strategy, the decision meant that Sanofi would have to proceed on the infringement case as pleaded by AstraZeneca, using the discovery already obtained and the normal processes for claim construction and proof at later stages, rather than obtaining a procedural order that would compel AstraZeneca to reframe its infringement theory through more granular particulars.
Why Does This Case Matter?
This case is significant for practitioners because it clarifies the boundary between (i) the minimum pleading requirements for patent infringement actions and (ii) attempts to use further and better particulars to force early claim construction or to obtain tactical narrowing of the patentee’s case. The decision reinforces that particulars serve fairness and procedural efficiency, not to compel a patentee to crystallise every interpretive argument at the pleading stage.
It also matters in the context of Singapore’s Medicines Act patent linkage regime. Although the substantive cause of action under s 12A is independent and requires only a prospect of infringement (as established in the earlier decision [2012] SGHC 16), the court’s approach shows that the pleading discipline of patent litigation still applies. Defendants cannot assume that the linkage framework reduces the need for proper particulars; conversely, plaintiffs are not required to provide more than what the rules and the “office” of particulars demand.
For law students and litigators, the case provides a useful roadmap for how courts interpret O 87A r 2(2). It demonstrates that the sufficiency of particulars is assessed by reference to the purposes of pleadings, the statutory requirement to identify infringed claims and provide at least one instance of each type of infringement, and the practical context created by discovery. The decision therefore supports a disciplined pleading approach: plaintiffs should plead clearly enough to identify the infringement theory and instances, while defendants should use discovery and claim construction processes rather than particulars applications to litigate interpretive disputes.
Legislation Referenced
- Rules of Court (Cap 322, R 5, 2006 Rev Ed): O 18 r 12
- Rules of Court (Cap 322, R 5, 2006 Rev Ed): O 87A r 2(2)
- Medicines Act (Cap 176, 1985 Rev Ed): s 12A(3)(a); s 12A(6) [CDN] [SSO]
- Medicines (Licensing, Standard Provisions and Fees) Regulations (Cap 176, S 74, 2000 Rev Ed): regulation 5B(4)
- Patents Act (Cap 221, Rev Ed 2005)
Cases Cited
- AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd [2012] SGHC 16
- [2013] SGHCR 7 (this case)
- Wenham Co Ltd v Champion Gas Lamp Co Ltd and Todlenhaupt and Co [1891] 8 RPC 22
- Marsden v Albrecht and Albrecht (1910) 27 RPC 785
Source Documents
This article analyses [2013] SGHCR 7 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.